Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2527-2530

  Raymond, Stéphanie ^a,b,c   Saliou, Adrien ^a   Delobel, Pierre ^a,b,c   Cazabat, Michelle ^a,c   Pasquier, Christophe ^a,c   Jeanne, Nicolas ^a,c   Sauné, Karine ^a,b,c   Massip, Patrice ^b,c   Marchou, Bruno ^b,c   Izopet, Jacques ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU PURPAN   (France)

Author keywords

Selection pressure; Ultra deep sequencing; V3 envelope region

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; VIRUS ENVELOPE PROTEIN; ANTIRETROVIRUS AGENT; VIRUS DNA; VIRUS RECEPTOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; DNA CONTENT; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; LONG TERM CARE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; PHENOTYPE; PHYLOGENY; SEQUENCE ANALYSIS; SPECIES DIVERSITY; TREATMENT DURATION; ULTRA DEEP SEQUENCING; VIRAL TROPISM; VIRUS LOAD; CLASSIFICATION; FEMALE; GENETIC VARIABILITY; GENETICS; GENOTYPE; GENOTYPING TECHNIQUE; HIGH THROUGHPUT SEQUENCING; HIV INFECTIONS; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MONONUCLEAR CELL; PHYSIOLOGY; VIROLOGY; VIRUS CULTURE;

ADULT; ANTI-RETROVIRAL AGENTS; DNA, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GENETIC VARIATION; GENOTYPE; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, HIV; VIRAL TROPISM; VIRUS CULTIVATION;

EID: 84904485194     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku147     Document Type: Article

References (20)

1. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183-8.
2. Izopet J, Cazabat M, Pasquier C, et al. Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. Virology 2002; 302: 393-404.
3. Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. JAcquir ImmuneDefic Syndr 2005; 38: 382-92.
4. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
5. Loman NJ,Misra RV, Dallman TJ, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012; 30: 434-9.
6. Raymond S, Saliou A, Nicot F, et al. Characterization of CXCR4-using HIV-1 during primary infection by ultra-deep pyrosequencing. J Antimicrob Chemother 2013; 68: 2875-81.
7. Delobel P, Nugeyre MT, Cazabat M, et al. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J Virol 2006; 80: 10229-36.
8. Raymond S, Delobel P, Mavigner M, et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol 2010; 47: 126-30.
9. Saliou A, Delobel P, Dubois M, et al. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother 2011; 55: 2831-6.
10. Däumer M, Kaiser R, Klein R, et al. Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis. BMC Med Inform Decis Mak 2011; 11: 30.
11. Tamura K, Peterson D, Peterson N, et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28: 2731-9.
12. Yang B. Statistical methods for detecting molecular adaptation. Trends Ecol Evol (Amst) 2000; 15: 496-503.
13. Seclen E, Garrido C, Gonzalez MD, et al. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 2010; 65: 1486-92.
14. Soulie C, Marcelin AG, Ghosn J, et al. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART. AIDS 2007; 21: 2243-5.
15. Soulie C, Lambert-Niclot S, Wirden M, et al. Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years. AIDS 2011; 25: 537-9.
16. Saracino A, Monno L, Cibelli DC, et al. Co-receptor switch during HAART is independent of virological success. J Med Virol 2009; 81: 2036-44.
17. Soulié C, Fourati S, Lambert-Niclot S, et al. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother 2010; 65: 749-51.
18. Martínez MA, Cabana M, Ibáñez A, et al. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 1999; 256: 180-7.
19. Wagner TA, McKernan JL, Tobin NH, et al. An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cells. J Virol 2013; 87: 1770-8.
20. Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477: 95-8.